NCT04979117

Brief Summary

A prospective study will be conducted to evaluate the diagnostic performance of SMI, gray scale US, color Doppler US and Power Doppler US.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 28, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 16, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 28, 2021

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 27, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 27, 2022

Completed
Last Updated

December 28, 2022

Status Verified

December 1, 2022

Enrollment Period

1.6 years

First QC Date

July 16, 2021

Last Update Submit

December 27, 2022

Conditions

Keywords

superb microvascular imagingdiagnosemicrovascularizationplantar fasciitis

Outcome Measures

Primary Outcomes (4)

  • Visual Analog Scale (VAS) Pain Score

    The patient will be asked to indicate his/her perceived pain intensity (most commonly) along a 100 mm horizontal line. This rating is then measured from the left edge gives the VAS score. A higher score indicates greater pain intensity and lower scores indicates less pain intensity.

    Each participant will be assessed only one time at the admission time to the outpatient clinic

  • Heel Tenderness Index (HTI)

    Heel tenderness index (HTI) will be assessed by physician; based on assessing pain on palpation (0=no pain, 1=painful, 2=painful and winces, 3=painful, winces and withdraws).

    Each participant will be assessed only one time at the admission time to the outpatient clinic

  • Foot Function Index (FFI)

    This index aims to measure the impact of foot pathology on function in terms of pain, disability and activity restriction. The FFI is a self-administered index consisting of 23 items divided into 3 sub-scales.

    Each participant will be assessed only one time at the admission time to the outpatient clinic

  • Ultrasonographic Evaluation; Superb Microvascular Imaging, GrayScale Imaging, Color Doppler Imaging, Power Doppler Imaging

    Vascular blood flow images from median nerve (enterrapted in carpal tunnel) obtained with Power Doppler and Superb microvascular imaging. \[ Time Frame: Each participant will be assessed only one time at the admission time to the outpatient clinic \] Four-stage classify will be use for grading these images; Grade 0: No vascularity in MN, Grade 1: One or two focal color-encoded spots in MN, Grade 2: One linear color-encoded line or more than two focal color-encoded spots in MN, Grade 3: More than one linear color-encoded line in MN

    Each participant will be assessed only one time at the admission time to the outpatient clinic

Study Arms (2)

Participants with plantar fasciitis

Participants with the diagnose of plantar fasciitis; typical anamnesis (exacerbating pain by the first steps in the morning or after rest and with prolonged standing). The emerge of local point tenderness over the heel and proximal fascia due to the pressure applied by the physician. Thickening of the plantar fascia greater than 4 mm in ultrasonographic evaluation. measurement

Device: Superb Microvascular Imaging (SMI) (Toshiba)

Volunteers who has not foot complaints.

Volunteers who were not diagnosed with Plantar Fasciitis and without foot or heel pain when taking the first steps in the morning, with plantar fascia thickness less than 4 mm, painless, symptom-free and which had no additional rheumatic disease.

Device: Superb Microvascular Imaging (SMI) (Toshiba)

Interventions

to determine whether there is a diagnostic value of SMI in Plantar Fasciitis and whether there is a superiority when compared Power Doppler and Color Doppler modalities.

Participants with plantar fasciitisVolunteers who has not foot complaints.

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

* Patients who diagnosed as Plantar Fasciitis as the first group * Healthy participants as the second group

You may qualify if:

  • Patients who diagnosed as Plantar Fasciitis
  • Age between 18-45

You may not qualify if:

  • History of foot trauma or surgery
  • Diabetes mellitus
  • Pregnancy,
  • Rheumatological diseases
  • For the second group:
  • asymptomatic foot,
  • no previous trauma or surgery on foot,
  • no history of systemic inflammatory disorders.
  • History of foot trauma or surgery
  • Diabetes mellitus
  • Pregnancy,
  • Rheumatological diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nigde Omer Halisdemir University

Niğde, 51700, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Fasciitis, PlantarDisease

Condition Hierarchy (Ancestors)

FasciitisMusculoskeletal DiseasesFoot DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ender Salbas, MD

    Omer Halisdemir University

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physical Medicine & Rehabilitation Specialist, MD

Study Record Dates

First Submitted

July 16, 2021

First Posted

July 28, 2021

Study Start

May 28, 2021

Primary Completion

December 27, 2022

Study Completion

December 27, 2022

Last Updated

December 28, 2022

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

We do not want to share IPD with any researchers.

Locations